Loading clinical trials...
Loading clinical trials...
Phase 1, Randomized, Blinded, Placebo-Controlled, Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Dapirolizumab Pegol (BIIB133) in Healthy Japanese and Caucasian Study Participants
Conditions
Interventions
BIIB133 (Dapirolizumab pegol)
Placebo
Locations
1
United States
Anaheim Clinical Trials
Anaheim, California, United States
Start Date
October 14, 2020
Primary Completion Date
April 8, 2021
Completion Date
April 8, 2021
Last Updated
April 18, 2023
NCT07310264
NCT06342713
NCT07472361
NCT06823947
NCT06649110
NCT07240675
Lead Sponsor
Biogen
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions